Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Mandema, J. W. et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 51, 715–728, doi: 10.1038/clpt.1992.84 (1992).
2. Tuk, B., van Oostenbruggen, M. F., Herben, V. M., Mandema, J. W. & Danhof, M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J. Pharmacol. Exp. Ther. 289, 1067–1074 (1999).
3. Bremer, F., Reulbach, U., Schwilden, H. & Schuttler, J. Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey. Ther. Drug Monit. 26, 643–649, doi: 10.1097/00007691-200412000-00010 (2004).
4. Spina, S. P. & Ensom, M. H. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27, 389–398, doi: 10.1592/phco.27.3.389 (2007).
5. Swart, E. L. et al. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur. J. Clin. Pharmacol. 62, 185–194, doi: 10.1007/s00228-005-0085-8 (2006).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献